{"id":48433,"date":"2024-01-22T23:00:00","date_gmt":"2024-01-22T21:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-presente-les-dernieres-donnees-dun-essai-de-phase-iii-evaluant-cabometyx-en-association-avec-une-immunotherapie-a-loccasion-de-ledition-2024-de-lasco-sur-les-cancers-genito-urinair\/"},"modified":"2024-07-23T12:50:46","modified_gmt":"2024-07-23T10:50:46","slug":"ipsen-presente-les-dernieres-donnees-dun-essai-de-phase-iii-evaluant-cabometyx-en-association-avec-une-immunotherapie-a-loccasion-de-ledition-2024-de-lasco-sur-les-cancers-genito-urinair","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-dernieres-donnees-dun-essai-de-phase-iii-evaluant-cabometyx-en-association-avec-une-immunotherapie-a-loccasion-de-ledition-2024-de-lasco-sur-les-cancers-genito-urinair\/","title":{"rendered":"Ipsen pr\u00e9sente les derni\u00e8res donn\u00e9es d’un essai de Phase III \u00e9valuant Cabometyx\u00ae en association avec une immunoth\u00e9rapie \u00e0 l’occasion de l’\u00e9dition 2024 de l’ASCO sur les cancers g\u00e9nito-urinaires"},"content":{"rendered":"